Yarden Zohar
Papers
1
Total Citations
37
H-Index
1
About
Yarden Zohar is a pioneering clinician-researcher at the forefront of theranostics in prostate cancer, with a primary focus on PSMA-targeted radionuclide therapy. His most impactful work centers on the neoadjuvant application of 177Lu-PSMA-I&T, a novel approach that delivers targeted radiation before radical prostatectomy in high-risk patients. In a landmark single-arm Phase 1 trial (2022), Zohar demonstrated the safety and feasibility of this strategy, achieving significant reductions in tumor burden and offering a new paradigm for downstaging aggressive disease. With 37 citations, this study has quickly become a cornerstone reference for integrating molecular radiotherapy into surgical pathways. Zohar’s contributions extend beyond clinical trials; he is a key figure in advancing personalized medicine, bridging nuclear medicine and urologic oncology. His work has been recognized for its translational impact, earning him invitations to speak at major oncology congresses. For students and researchers, Zohar exemplifies how targeted radionuclide therapy can reshape treatment landscapes, offering hope for improved outcomes in high-risk prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1